He quit medicine in 1988 and moved to New Jersey, where he initially took up a trainee post in the US headquarters of Sandoz, before becoming product manager for a newly approved pancreatic cancer drug, a somatosta- tin analog called Sandostatin (octreotide). By 1993, Vasella was back in ...